27 Mar 2008 - Oncothyreon Inc. announced that the U.S. Patent and Trademark office has issued a patent for PX-867, a small molecule compound currently in preclinical development. The newly issued patent, U.S. Patent No. 7,335,679, includes claims covering both composition of matter of PX-867 and pharmaceutical preparations containing PX-867.
PX-867 is an inhibitor of the phosphatidylinositol-3-kinase (PI-3-kinase)/PTEN/Akt pathway, the same pathway targeted by Oncothyreon's small molecule compound PX-866, which is expected to enter clinical development in 2008. Signaling through this pathway plays a critical role in the survival of cancer cells, and also contributes to a number of other disease states, including cardiovascular disease and autoimmune disease. The preclinical development for PX-867 has focused on cardiovascular disease. In particular, the compound has demonstrated activity as a coating on intravascular stents in preclinical models of atherosclerotic disease.
"We intend to seek a partner to develop PX-867 in non-oncology indications, particularly in cardiovascular applications, while focusing our internal development efforts on PX-866 in oncology, our core area of expertise," said Robert L. Kirkman, M.D. President and CEO of Oncothyreon. "We expect to file an Investigational New Drug Application for PX-866 in the coming quarter and to initiate a Phase 1 trial soon thereafter."
 |
www.bionity.com/news/e/80039 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/80039 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |